Celltrion and Lonza have entered a contract manufacturing agreement to produce drug substance for Remsima, a biosimilar approved by the EMA and the FDA for a number of autoimmune diseases including Crohn’s disease and rheumatoid arthritis.   To complement its existing capacity of 190,000L of drug substance per year from two plants in Korea, Celltrion has looked to Lonza to diversify its supply base and meet the increasing demands of the biosimilar market.   The Remisma drug substance will be...